Dicot Pharma has successfully completed a pre-IND meeting with FDA
Uppsala, Sweden, July 2, 2024. Dicot Pharma AB today announced that the company has held a pre-IND meeting with the US Food and Drug Administration (FDA) and received positive feedback on the development program for the drug candidate LIB-01. This is considered a validation of the quality of the program and is an important step towards an application to include US study centers in future clinical studies and to ensure that the current development plan meets the regulatory requirements for future market approval in the US.Dicot Pharma has recently had its first formal interaction with the US